Explore 3 Stock Ideas & Industry Insights Download Free Report

Ligand Pharmaceuticals Inc General Contingent Value Rt

Company price
None USD 0.00(0%)
Last update at 2026-11-16T10:21:01.761474Z
Market Cap
0.00M

Momentum Score

…

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
290.54M
Revenue Per Share
14.75
Gross Profit TTM
235.92M
Debt / Equity
0.45
ROE
21.96%
Net Debt
-282.03M
ROCE
10.75%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 158.96M 2.52M 63.66M 36.01M 47.30M
Net income 124.45M 9.07M 52.15M -5.22M 37.46M
Selling general administrative 92.45M 78.65M 52.79M 70.06M 57.48M
Gross profit 220.83M 120.80M 88.03M 196.25M 214.96M
Ebit 163.68M 5.55M 64.32M 34.21M 47.35M
Ebitda 197.45M 42.94M 101.73M 3.04M 98.42M
Depreciation and amortization 33.77M 37.38M 37.41M -31.18M 51.07M
Operating income 47.20M 23.02M 9.82M 34.21M 47.35M
Other operating expenses 220.89M 144.11M 121.49M 193.21M 198.24M
Interest expense 4.71M 3.04M 0.66M -1.80M -19.63M
Income tax expense 34.51M -6.55M 9.84M 41.23M 9.84M
Total revenue 268.09M 167.13M 131.31M 196.25M 277.13M
Total operating expenses 173.63M 97.78M 78.20M 106.14M 136.06M
Cost of revenue 47.26M 46.33M 43.29M - 62.18M
Total other income expense net 111.76M -20.50M 53.84M 1.80M -0.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1560.64M 941.77M 787.22M 762.67M 1297.59M
Intangible assets 225.44M 266.65M 366.90M 342.45M 551.04M
Other current assets 30.02M 22.90M 3.84M 8.01M 10.86M
Total liab 543.42M 111.33M 86.30M 165.18M 476.43M
Total stockholder equity 1017.21M 830.44M 700.91M 597.49M 821.16M
Other current liab 31.88M 33.63M 12.72M 84.93M 16.06M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings 608.09M 498.98M 503.02M 450.86M 449.09M
Good will 101.54M 105.25M 103.37M 105.67M 181.21M
Cash 733.52M 72.31M 22.95M 45.01M 19.52M
Total current liabilities 37.45M 37.11M 16.78M 98.81M 41.66M
Current deferred revenue - 1.28M 1.22M 8.53M 11.00M
Net debt -282.03M -65.20M -16.79M 42.74M 338.39M
Short term debt 1.09M 1.29M 0.41M 0.04M 6.21M
Short long term debt total 455.69M 7.11M 6.17M 87.75M 357.91M
Other stockholder equity 400.65M 337.38M 197.88M 147.59M 372.97M
Total current assets 832.27M 331.56M 237.43M 263.60M 464.75M
Short term investments 558.59M 183.86M 147.35M 166.86M 321.59M
Net receivables 59.60M 38.38M 39.31M 30.42M 85.45M
Inventory 9.13M 14.11M 23.97M 13.29M 27.33M
Accounts payable 3.24M 5.23M 2.43M 5.31M 8.40M
Accumulated other comprehensive income 8.46M -5.94M -0.82M -0.98M -0.92M
Non currrent assets other 198.66M 202.53M 5.92M 14.92M 29.06M
Non current assets total 728.37M 610.22M 549.79M 499.07M 832.84M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities -377.32M -143.66M -11.68M - -
Total cash from financing activities 428.22M 97.57M -59.00M -275.99M -137.76M
Net income 124.45M -4.03M 11.70M -33.36M 57.14M
Change in cash 102.62M 49.35M -22.05M 25.48M -28.44M
Begin period cash flow 72.31M 22.95M 45.01M 19.52M 47.96M
End period cash flow 174.93M 72.31M 22.95M 25.48M 19.52M
Total cash from operating activities 49.36M 97.05M 48.63M 137.85M 78.80M
Depreciation 33.70M 33.91M 35.20M 51.55M 51.07M
Other cashflows from investing activities -27.44M -111.75M 0.42M - -
Change to inventory 4.99M 9.62M -10.87M 12.06M -0.43M
Change to account receivables -21.74M -6.46M -4.38M 55.32M -28.62M
Sale purchase of stock -15.00M - - - -
Other cashflows from financing activities -9.77M -5.14M -4.55M -275.94M 18.00M
Capital expenditures 0.45M 1.82M 53.85M 17.92M 8.76M
Change in working capital -12.66M 19.36M -34.40M 64.04M -59.58M
Stock based compensation 46.85M 41.09M 25.74M 60.28M 38.78M
Other non cash items -118.81M 6.73M 10.39M -25.38M -
Free cash flow 48.91M 95.23M -5.22M 119.93M 70.04M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
DOGEF
Orsted A/S
0.13
0.62%
21.25 28.82 0.66 6.50 0.07
TBB
AT&T Inc. 5.35% GLB NTS 66
-
-%
17.63 4.60 - - -
CCZ
Comcast Holdings Corp
-
-%
62.32 55.07 - - -
STMZF
Scottish Mortgage Investment Trust PLC
-0.12
0.63%
19.72 - - 2.56 -

Profile*

Ligand Pharmaceuticals Inc General Contingent Value Rt

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

555 Heritage Drive, Jupiter, FL, United States, 33458

858 550 7500

47

Name Title Year Born
Mr. Todd C. Davis Ph.D. CEO & Director 1961
Mr. Octavio Espinoza Chief Financial Officer 1971
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 1975
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development NA
Ms. Melanie J. Herman CPA Executive Director of Investor Relations and Financial Planning & Analysis 1979
Ms. Marjorie Fackovec Head of People Operations NA
Dr. Keith Marschke Ph.D. Senior Vice President of Biology & Scientific Affairs NA
Dr. Vincent D. Antle Ph.D. Senior Vice President of Technical Operations & QA - Capitsol 1969
Dr. Karen R. Reeves M.D. Senior VP of Investments & Head of Clinical Strategy 1950
Mr. Richard B. Baxter Senior VP of Investment Operations 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…